Form 8.3 - The Vanguard Group, Inc.: Sanofi
The Vanguard Group, Inc. ( IRSH)
Ap19
FORM 8.3
IRISH TAKEOVER PANELDISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Ap20
1. Dealings (Note 4)
(a) Purchases and sales
(b) Derivatives transactions (other than options transactions)
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
(ii) Exercising
(e) Other dealings (including transactions in respect of new securities) (Note 4)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Is a Supplemental Form 8 attached? (Note 9) NO
|
Category Code: | RET - Sanofi |
TIDM: | IRSH |
LEI Code: | 5493002789CX3L0CJP65 |
Sequence No.: | 205631 |
EQS News ID: | 1503367 |
End of Announcement | EQS News Service |
|
Sanofi S.A. Stock
Our community is currently high on Sanofi S.A. with 4 Buy predictions and 0 Sell predictions.
As a result the target price of 99 € shows a slightly positive potential of 8.17% compared to the current price of 91.52 € for Sanofi S.A..